Team 13 : Laurent Yvan-Charvet
ATIP Avenir : Metabolism and cancer
Previous activities

Dr. Laurent Yvan-Charvet obtained his Ph.D. in Endocrinology in 2005 from the University of Paris XI, France. He was the recipient of the Roger Davis Award in 2010, finalist of the I.H. Page Young Investigator Award in 2011 and recipient of the EAS young Investigator award in 2013.

His research work at Columbia University has been mainly focused on two ATP-binding cassette transporters ABCA1 and ABCG1 that mediated the cholesterol efflux potential of HDL-cholesterol (good cholesterol). These transporters are central to the metabolic complications of the immune and hematopoietic systems not only in cancer but also in cardiometabolic diseases such as atherosclerosis. Therapies aimed at raising HDL-C are currently under Phase III clinical trials.

After a contribution to the development of new therapeutics for cardiovascular diseases at Pfizer, his current research interest as a group leader lies in immune and hematopoietic cell metabolism in diseases.

Our research program primarily focuses on the 'Metabolism of the immune and hematopoietic systems in cancer and cardiometabolic diseases with the aim to gain insight in immune metabolic complications observed in these diseases. We are currently focusing on the identification of novel metabolic pathways that could act independently or in synergy on the metabolism of immune and hematopoietic systems in myeloproliferative disease, lung cancer and cardiometabolic diseases.

The team is dedicated to achieve a deeper understanding of the metabolism of the immune and hematopoietic system in cancer and cardiometabolic diseases with the hope of identifying new candidate targets for therapeutic interventions or new predictors of disease outcomes.

Link and contact:


Research Projects

Axe 1 : Metabolic abnormalities of the immune and hematopoietic systems associated to cancer cachexia. I. Role of metabolic pathways in cachexia associated to myeloproliferative disease and lung cancer. II. Identification of novel mutations in the cholesterol efflux transporter ABCA1 in myeloproliferative disorder.

Axe 2 : Metabolic abnormalities of the immune and hematopoietic systems in cardiometabolic diseases. II. Role of glycolytic pathways on cardiometabolic diseases II. Role of cholesterol efflux pathways on cardiometabolic diseases

Major Publications


Murphy AJ, Yvan-Charvet L. Adipose modulation of ABCG1 uncovers an intimate link between sphingomyelin and triglyceride storage. Diabetes. 2015 Mar;64(3):689-92

Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015 Jan 23;15(2):104-16.


Murphy AJ, Sarrazy V, Wang N, Bijl N, Abramowicz S, Westerterp M, Welch CB, Schuetz JD, Yvan-Charvet L. Deficiency of ATP-Binding Cassette Transporter B6 in Megakaryocyte Progenitors Accelerates Atherosclerosis in Mice. Arterioscler Thromb Vasc Biol. 2014 Feb 6.


Ganda A, Magnusson M, Yvan-Charvet L, Hedblad B, Engström G, Ai D, Wang TJ, Gerszten RE, Melander O, Tall AR. Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis. Circulation. 2013 Mar 5;127(9):988-96

Gautier EL, Westerterp M, Bhagwat N, Cremers S, Shih A, Abdel-Wahab O, Lütjohann D, Randolph GJ, Levine RL, Tall AR, Yvan-Charvet L. HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med. 2013 Feb 11;210(2):339-53.


Tall AR, Yvan-Charvet L, Westerterp M, Murphy AJ. Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis. Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2547-52

Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, Tall AR, Yvan-Charvet L. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell. 2012 Aug 3;11(2):195-206.

Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012 Apr 17;125(15):1905-19

Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR. Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta. (2012), 1821:513-21


Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, Wang M, Sanson M, Abramowicz S, Welch C, Bochem AE, Kuivenhoven JA, Yvan-Charvet L, Tall AR. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest. 2011 Oct;121(10):4138-49

Kuo CL, Murphy AJ, Sayers S, Li R, Yvan-Charvet L, Davis JZ, Krishnamurthy J, Liu Y, Puig O, Sharpless NE, Tall AR, Welch CL. Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation. Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2483-92.

Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. (2011), 79:162-168.

Gautier EL, Yvan-Charvet L. HDL and its transporters ABCA1 and ABCG1 regulate innate immunity and hematopoietic stem cell proliferation. Med Sci (Paris). (2011), 27:9-11.


Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry R, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR. ATP binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. (2010), 328: 1689-93.

Yvan-Charvet L, Pagler T, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res. (2010), 106: 1861-69.

Terasaka N, Westerterp M, Koetsveld J, Fernadez-Hernando C, Yvan-Charvet L, Wang N, Sessa WC Tall AR. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol. (2010), 30:2219-25

Yvan-Charvet L, Kling J, Pagler TA, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR. Cholesterol efflux potential and anti-inflammatory properties of HDL following treatment with Niacin or Anacetrapib. Arterioscler Thromb Vasc Biol. (2010), 30: 1430-38.

Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. (2010), 30 :139.

Before 2009

Yvan-Charvet L, Massiera F, Lamande N, Ailhaud G, Teboul M, Moustaid-Moussa N, Gasc JM, Quignard-Boulange A. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology. (2009), 150:1421-8.

Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, Ishibashi M, Li R, Wang N, Tall AR. Increased inflammatory gene expression in ABC transporter deficient macrophages: free cholesterol accumulation, increased signaling via Toll-like receptors and neutrophil infiltration of atherosclerotic lesions. Circulation. (2008),118:1837-47.

Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. (2008), 7:365-75.

Masson D, Yvan-Charvet L. Raising HDl-cholesterol: the future drug therapy for atherosclerosis? Med Sci (Paris). (2008), 24:341-3.

Teraska N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R, Pagler T Li R, Welch CL, Goldberg IJ, Tall AR. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest. (2008), 118:3701-13.

Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, Kim TW, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. Faseb J. (2008), 22:1073-82.

Yvan-Charvet L, Pagler TA, Wang N, Senokuchi T, Brundert M, Li H, Rinninger F, Tall AR. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. J Lipid Res. (2008), 49: 107-14.

Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Combined deficiency of ABCA1 and ABCG1 leads to myocardial foam cell invasion and accelerated atherosclerosis. J Clin Invest. (2007), 117: 3900-8.

Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR. Inhibition of cholesteryl ester transfer protein by Torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. (2007), 27: 1132-8.

Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. (2007), 27:257-60.

Yvan-Charvet L, Bobard A, Bossard P, Massiera F, Rousset X, Ailhaud G, Teboul M, Ferre P, Dagher G, Quignard-Boulange A. In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Arterioscler Thromb Vasc Biol. (2007), 27: 1340-5.

Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA. (2007), 104:15093-8.

Cui D, Thorp E, Li Y, Wang N, Yvan-Charvet L, Tall AR, Tabas I. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol. (2007), 82:1040-50.




Home   Top of Page Publications
Team leader

Clinical researcher
Research assistant
Publications   Top of Page